Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru

OBJECTIVE: To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs. RESULTS: There were 279 M. tuberculosis isolates from the two cohorts (2004–2005:...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwalb, Alvaro, Cachay, Rodrigo, Meza, Ericka, Cáceres, Tatiana, Blackman, Amondrea, Maruri, Fernanda, Sterling, Timothy R., Gotuzzo, Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591909/
https://www.ncbi.nlm.nih.gov/pubmed/34776013
http://dx.doi.org/10.1186/s13104-021-05832-0
_version_ 1784599354082852864
author Schwalb, Alvaro
Cachay, Rodrigo
Meza, Ericka
Cáceres, Tatiana
Blackman, Amondrea
Maruri, Fernanda
Sterling, Timothy R.
Gotuzzo, Eduardo
author_facet Schwalb, Alvaro
Cachay, Rodrigo
Meza, Ericka
Cáceres, Tatiana
Blackman, Amondrea
Maruri, Fernanda
Sterling, Timothy R.
Gotuzzo, Eduardo
author_sort Schwalb, Alvaro
collection PubMed
description OBJECTIVE: To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs. RESULTS: There were 279 M. tuberculosis isolates from the two cohorts (2004–2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0–0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0–0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru.
format Online
Article
Text
id pubmed-8591909
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85919092021-11-15 Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru Schwalb, Alvaro Cachay, Rodrigo Meza, Ericka Cáceres, Tatiana Blackman, Amondrea Maruri, Fernanda Sterling, Timothy R. Gotuzzo, Eduardo BMC Res Notes Research Note OBJECTIVE: To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs. RESULTS: There were 279 M. tuberculosis isolates from the two cohorts (2004–2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0–0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0–0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru. BioMed Central 2021-11-14 /pmc/articles/PMC8591909/ /pubmed/34776013 http://dx.doi.org/10.1186/s13104-021-05832-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Note
Schwalb, Alvaro
Cachay, Rodrigo
Meza, Ericka
Cáceres, Tatiana
Blackman, Amondrea
Maruri, Fernanda
Sterling, Timothy R.
Gotuzzo, Eduardo
Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
title Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
title_full Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
title_fullStr Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
title_full_unstemmed Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
title_short Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
title_sort fluoroquinolone susceptibility in first-line drug-susceptible m. tuberculosis isolates in lima, peru
topic Research Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591909/
https://www.ncbi.nlm.nih.gov/pubmed/34776013
http://dx.doi.org/10.1186/s13104-021-05832-0
work_keys_str_mv AT schwalbalvaro fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu
AT cachayrodrigo fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu
AT mezaericka fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu
AT cacerestatiana fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu
AT blackmanamondrea fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu
AT marurifernanda fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu
AT sterlingtimothyr fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu
AT gotuzzoeduardo fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu

Ejemplares similares